This is likely due to Tirzepatides additional mechanism of action through GIP, enhancing its ability to decrease appetite and food intake
As GLP-1 drugs continue to gain traction, with roughly 9% of US adults currently using them, CPG leaders expect a corresponding shift in the food and beverages sector
Studies show similar effectiveness between men and women, and there is no "masculinizing" effect as with certain hormonal supplements
Key 12-week findings from the human trial include: 140% increase of GLP-1 on average 92% of participants lost weight , with an average of 11 pounds 92% saw a reduction in total body fat , with up to a 5.5% decrease 71% experienced a reduction in visceral fat , with up to a 27% decrease 100% of subjects who lost weight (92% of total subjects) maintained or saw an increase in muscle % , with up to a 2.7% increase No side effects were reported, including gastrointestinal issues* 85% agreed their food cravings decreased * 95% agreed their sugar cravings decreased * 96% agreed their portion sizes at each meal decreased * 85% agreed they now eat for health, not emotional reasons * 82% felt more in control of their relationship with food * * The clinical trial builds on successful in vitro research, which found that the MindBody GLP-1 System significantly increased GLP-1 production in L-cells by activating key genes
They also produce smaller injection volumes, which means less waste if you accidentally overdraw or need to expel air bubbles
